Last $0.51 USD
Change Today +0.01 / 2.00%
Volume 900.0
CBIA On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

canopus biopharma inc (CBIA) Snapshot

Open
$0.51
Previous Close
$0.50
Day High
$0.51
Day Low
$0.51
52 Week High
07/15/14 - $0.95
52 Week Low
07/31/14 - $0.10
Market Cap
--
Average Volume 10 Days
230.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CANOPUS BIOPHARMA INC (CBIA)

Related News

No related news articles were found.

canopus biopharma inc (CBIA) Related Businessweek News

No Related Businessweek News Found

canopus biopharma inc (CBIA) Details

Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. It also provides antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceutricals. The company was founded in 1996 as Canopus Corporation and changed its name in 2007. Canopus BioPharma Incorporated is based in Studio City, California.

canopus biopharma inc (CBIA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

canopus biopharma inc (CBIA) Key Developments

Canopus BioPharma Inc. Announces Results from Compassionate Study in Hepatitis C patients in China

Canopus BioPharma Inc. announced topline results from a Compassionate Clinical Trial in China, evaluating the twice daily oral administration of Mogroside IV (Mogrovir(TM)). Mogrovir(TM) is a Toll-like receptor agonist and stimulator of the patient's immune system. Mogrovir(TM) was administered orally in combination with Ribavirn (RBV), for the treatment of Genotype 1, treatment naive Hepatitis C (HCV) patients. The study showed a statistically significant result regarding the improvement of both liver function and increased blood platelet counts. A selection of patients in the trial also showed a statistically significant reduction in HCV viral-load levels, in the three month follow up period post-therapy. HCV Viral-load in these specific patients were approaching zero after a period of 180 days (90 days Mogrovir(TM) Treatment and 90 days follow-up). This fact confirmed the immune activation effects which are expected from the immune activation characteristics of Mogrovir(TM). Twenty eight patients were enrolled in the Canopus BioPharma study and all patients completed the study, without any toxicity or negative side-effects being documented. Compared to baseline, significant improvements were observed for patients in malaise, anorexia, food intake, abdominal distension and sleep at day 90 of the study. Canopus BioPharma is currently co-ordinating with study centres in Europe and the USA to duplicate the results observed from this Chinese study. Since Hepatitis C and the Dengue Virus are both members of the Flavivirus family, Canopus BioPharma has initiated discussions in Singapore and Thailand with the intention of commencing patient studies with Mogrovir(TM) alone for the treatment of Dengue viral infections in patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBIA:US $0.51 USD +0.01

CBIA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CBIA.
View Industry Companies
 

Industry Analysis

CBIA

Industry Average

Valuation CBIA Industry Range
No financial data is available for CBIA.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CANOPUS BIOPHARMA INC, please visit www.canopusbiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.